Galectin Therapeutics News

Galectin Therapeutics Presents Clinical Data on NAVIGATE Trial for Esophageal Varices in MASH Cirrhosis at AASLD 2024

Quiver QuantitativeNov 18 08:13 ET

Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting

BenzingaNov 18 08:01 ET

Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More

Seeking AlphaNov 18 00:09 ET

H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11

Moomoo NewsNov 15 07:33 ET · Ratings

Optimistic Buy Rating for Galectin Therapeutics: Strategic Trial Design and Financial Stability Boost Prospects

TipRanksNov 15 06:35 ET · Ratings

Galectin Therapeutics Reports Increased Q3 Losses

TipRanksNov 14 23:24 ET

Galectin Therapeutics Believes It Has Sufficient Cash to Fund Planned Ops and Research Through May >GALT

Dow JonesNov 14 08:10 ET

Galectin Therapeutics: NAVIGATE Trial on Track for Top-Line Results in Dec >GALT

Dow JonesNov 14 08:10 ET

Galectin Therapeutics | 8-K: Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

SECNov 14 08:01 ET

Express News | Galectin Therapeutics Q3 2024 GAAP EPS $(0.18) Misses $(0.12) Estimate

BenzingaNov 14 08:00 ET

Press Release: Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Dow JonesNov 14 08:00 ET

Galectin Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 14 07:56 ET · Announcements

Express News | Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (Aasld) 2024 Liver Meeting

ReutersOct 15 08:00 ET

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

GlobeNewswireOct 15 08:00 ET

Galectin Therapeutics Unveils Future Plans and Drug Potential

TipRanksSep 9 08:28 ET

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Yahoo FinanceSep 3 08:30 ET

Buy Rating Affirmed for Galectin Therapeutics Ahead of Phase 2b Interim Analysis and With Strong Cash Position

TipRanksAug 20 04:45 ET · Ratings

Express News | HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

BenzingaAug 16 06:41 ET

Galectin Therapeutics Analyst Ratings

BenzingaAug 16 06:39 ET · Ratings

Galectin Therapeutics 2Q Net $12.4M >GALT

Dow JonesAug 13 08:04 ET